SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

04 Nov 2022 Evaluate
A fair growth of 8.57% in the revenue at Rs. 41512.70 millions was reported in the September 2022 quarter as compared to Rs. 38234.50 millions during year-ago period.Net profit declined -7.93% to Rs. 7051.90 millions from Rs. 7659.50 millions.The company reported a degrowth in operating Profit to 11533.30 millions from 11586.10 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 41512.70 38234.50 8.57 73084.00 73341.20 -0.35 130917.90 113027.10 15.83
Other Income 922.80 1977.30 -53.33 2099.60 2773.90 -24.31 6667.00 2302.80 189.52
PBIDT 11533.30 11586.10 -0.46 21283.90 23563.90 -9.68 40331.70 32976.90 22.30
Interest 75.00 76.00 -1.32 97.10 156.00 -37.76 269.30 450.70 -40.25
PBDT 11458.30 11510.10 -0.45 21186.80 23407.90 -9.49 40062.40 32526.20 23.17
Depreciation 1760.10 1389.70 26.65 2834.70 2529.40 12.07 4600.10 4686.20 -1.84
PBT 9698.20 10120.40 -4.17 18352.10 20878.50 -12.10 35462.30 27840.00 27.38
TAX 2646.30 2460.90 7.53 4860.20 5333.90 -8.88 8568.40 7393.50 15.89
Deferred Tax -6.00 30.20 -119.87 -118.50 -59.10 100.51 -304.00 -169.20 79.67
PAT 7051.90 7659.50 -7.93 13491.90 15544.60 -13.21 26893.90 20446.50 31.53
Equity 1614.00 1613.30 0.04 1614.00 1613.30 0.04 1613.60 1612.90 0.04
PBIDTM(%) 27.78 30.30 -8.32 29.12 32.13 -9.36 30.81 29.18 5.59

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×